MA34836B1 - Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations - Google Patents

Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations

Info

Publication number
MA34836B1
MA34836B1 MA36127A MA36127A MA34836B1 MA 34836 B1 MA34836 B1 MA 34836B1 MA 36127 A MA36127 A MA 36127A MA 36127 A MA36127 A MA 36127A MA 34836 B1 MA34836 B1 MA 34836B1
Authority
MA
Morocco
Prior art keywords
condenses
substituted
heterocyclic compounds
nitrogenic
nitrogenic heterocyclic
Prior art date
Application number
MA36127A
Other languages
English (en)
Inventor
Lewis J Gazzard
Emily Hanan
Samuel Kintz
Joseph P Lyssikatos
Hans Edward Purkey
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34836B1 publication Critical patent/MA34836B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

CETTE INVENTION CONCERNE DE NOUVEAUX COMPOSÉS DE FORMULE GÉNÉRALE (I) OÙ X1 EST N OU N+O-, ET UN DES X2, X3 ET X4 EST N OU N+-O-, LE RESTE DES X2, X3 ET X4 ÉTANT C. R2, R3, R4, R5, R6, A, B ET Y SONT TELS QUE DÉCRITS DANS LA PRÉSENTE. DE PLUS, DES COMPOSITIONS CONTENANT LES COMPOSÉS DE FORMULE (I) ET DES PROCÉDÉS POUR LES UTILISER SONT, EN OUTRE, DÉCRITS.
MA36127A 2010-12-17 2011-12-14 Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations MA34836B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201061424567P 2010-12-17 2010-12-17
PCT/EP2011/072666 WO2012080284A2 (fr) 2010-12-17 2011-12-14 Composés hétérocycliques azotés 6,6-condensés substitués et leurs utilisations

Publications (1)

Publication Number Publication Date
MA34836B1 true MA34836B1 (fr) 2014-01-02

Family

ID=45418653

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36127A MA34836B1 (fr) 2010-12-17 2011-12-14 Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations

Country Status (18)

Country Link
US (3) US8623889B2 (fr)
EP (1) EP2651899B1 (fr)
JP (2) JP6026427B2 (fr)
KR (1) KR20130129244A (fr)
CN (1) CN103261167B (fr)
AR (1) AR084280A1 (fr)
AU (1) AU2011344270A1 (fr)
BR (1) BR112013013790A2 (fr)
CA (1) CA2817460A1 (fr)
CO (1) CO6741198A2 (fr)
CR (1) CR20130338A (fr)
EA (1) EA026115B1 (fr)
EC (1) ECSP13012771A (fr)
MA (1) MA34836B1 (fr)
MX (1) MX2013006101A (fr)
PH (1) PH12013501489A1 (fr)
TW (1) TW201307292A (fr)
WO (1) WO2012080284A2 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809068B2 (en) 2006-04-18 2014-08-19 Advanced Liquid Logic, Inc. Manipulation of beads in droplets and methods for manipulating droplets
US7439014B2 (en) * 2006-04-18 2008-10-21 Advanced Liquid Logic, Inc. Droplet-based surface modification and washing
MX2012015143A (es) * 2010-06-30 2013-07-03 Amgen Inc Compuestos heterociclicos que contienen nitrogeno como inhibidores de pi3k delta.
EA026115B1 (ru) * 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
RU2015113597A (ru) * 2012-09-14 2016-11-10 Итернити Байосайенс Инк. Производные аминоизохинолина в качестве ингибиторов протеинкиназы
WO2014044846A1 (fr) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. Dérivés de 3-(aryl- ou hétéroaryl-amino)-7-(3,5-diméthoxyphényl)isoquinoline comme inhibiteurs de fgfr utiles pour le traitement de troubles prolifératifs ou de la dysplasie
WO2014087165A1 (fr) * 2012-12-06 2014-06-12 University Of Bath Inhibiteurs de tankyrase
AU2014302595B2 (en) * 2013-06-24 2018-08-02 Amgen Inc. Method for the preparation of [1,2,4]-triazolo[4,3-a]pyridines
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
JP6759514B2 (ja) 2014-08-01 2020-09-23 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ ブロモドメインに対して活性な化合物
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
AR108326A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
EP3464270B1 (fr) * 2016-05-24 2022-02-23 Genentech, Inc. Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
US11168068B2 (en) 2016-07-18 2021-11-09 Janssen Pharmaceutica Nv Tau PET imaging ligands
US20190241573A1 (en) * 2016-07-20 2019-08-08 Glaxosmithkline Intellectual Property Development Limited Isoquinoline derivatives as perk inhibitors
EP3601259B1 (fr) 2017-03-30 2022-02-23 F. Hoffmann-La Roche AG Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
WO2018213219A1 (fr) * 2017-05-15 2018-11-22 University Of Houston System Pyrido[2,3-d]pyrimidin-7ones et composés apparentés utilisés en tant qu'inhibiteurs de protéine kinases
WO2018216705A1 (fr) * 2017-05-23 2018-11-29 国立大学法人京都大学 Agent prophylactique et/ou thérapeutique contre des maladies neurodégénératives
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses
AU2018346051B2 (en) * 2017-10-02 2022-11-10 1st Biotherapeutics Inc. Benzothiazol compounds and methods using the same for treating neurodegenerative disorders
US10604514B2 (en) 2017-10-19 2020-03-31 Samumed, Llc 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof
WO2019084496A1 (fr) 2017-10-27 2019-05-02 Samumed, Llc 6-(hétéroaryle à 5 chaînons)isoquinolin-3-yl-(hétéroaryle à 5 chaînons)carboxamides, leur préparation et leur utilisation
WO2019084497A1 (fr) 2017-10-27 2019-05-02 Samumed, Llc 6-(hétéroaryle et aryle à 6 chaînons)isoquinolin-3-yl carboxamides, leur préparation et leur utilisation
US10703748B2 (en) 2017-10-31 2020-07-07 Samumed, Llc Diazanaphthalen-3-yl carboxamides and preparation and use thereof
CN111868058B (zh) * 2018-05-25 2023-06-13 上海和誉生物医药科技有限公司 一种fgfr抑制剂、其制备方法和在药学上的应用
WO2019242587A1 (fr) * 2018-06-19 2019-12-26 上海和誉生物医药科技有限公司 Inhibiteur hautement sélectif de fgfr i, son procédé de préparation et son utilisation
TW202019905A (zh) 2018-07-24 2020-06-01 瑞士商赫孚孟拉羅股份公司 異喹啉化合物及其用途
TW202024053A (zh) 2018-10-02 2020-07-01 美商建南德克公司 異喹啉化合物及其用途
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
GB201901760D0 (en) 2019-02-08 2019-03-27 Syngenta Crop Protection Ag Herbicidal compounds
AU2020224401A1 (en) * 2019-02-22 2021-10-14 1ST Biotherapeutics, Inc. Imidazopyridinyl compounds and use thereof for treatment of neurodegenerative disorders
EP3934702B1 (fr) * 2019-03-07 2024-05-08 1st Biotherapeutics, Inc. Dérivé de benzothiazole marqué au [18f] en tant que radiotraceur tep
JP7691974B2 (ja) * 2019-07-25 2025-06-12 キュラデブ ファーマ ピーブイティー． リミテッド アセチル補酵素ａシンテターゼ短鎖２（ａｃｓｓ２）の小分子阻害剤
GB201915831D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) * 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
KR20230104781A (ko) 2020-10-05 2023-07-10 인라이븐 테라퓨틱스, 인크. Bcr-abl 티로신 키나아제의 억제를 위한 5- 및 6-아자인돌 화합물
EP4236950A4 (fr) * 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC Amides isoquinoline liés à n en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations associées
JP2023554062A (ja) * 2020-12-18 2023-12-26 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規アリール－ピリド－ピリミジン－オン誘導体
CN112898273B (zh) * 2021-03-30 2022-05-31 海南锦瑞制药有限公司 伏立康唑的合成方法及应用
CA3229293A1 (fr) * 2021-09-10 2023-03-16 Pui Yee Ng Derives de 6-aza-quinoleine et utilisations associees
WO2023055679A1 (fr) * 2021-10-01 2023-04-06 Merck Sharp & Dohme Llc Amides isoquinoline liés à c en tant qu'inhibiteurs de lrrk2, compositions pharmaceutiques et utilisations associées
CN114573460B (zh) * 2022-03-18 2024-04-26 北京格林凯默科技有限公司 3-溴-n,n-二甲基苯胺的制备方法
CN114605267B (zh) * 2022-03-18 2024-02-23 北京格林凯默科技有限公司 2-溴-n,n-二甲基苯胺的制备方法
MX2024011545A (es) 2022-03-23 2024-09-26 Ideaya Biosciences Inc Compuestos de indazol sustituidos con piperazina como inhibidores de parg.
AU2023358792A1 (en) * 2022-10-14 2025-04-17 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024098001A1 (fr) * 2022-11-04 2024-05-10 Enliven Inc. Composés de naphthyridone pour l'inhibition de raf kinases
WO2024097953A1 (fr) * 2022-11-04 2024-05-10 Enliven Inc. Composés de naphtyridine pour l'inhibition de kinases raf

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535321A (en) 1967-12-01 1970-10-20 Smithkline Corp 2-carbalkoxyaminodihydroquinazolines
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
DE3034001A1 (de) * 1980-09-10 1982-04-22 Hoechst Ag, 6000 Frankfurt Isochinolinderivate, verfahren zu ihrer hersellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
AU779908B2 (en) 1999-09-10 2005-02-17 Merck & Co., Inc. Tyrosine kinase inhibitors
AU1053501A (en) * 1999-11-02 2001-05-14 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
DE10021246A1 (de) 2000-04-25 2001-10-31 Schering Ag Substituierte Benzoesäureamide und deren Verwendung als Arzneimittel
US6822097B1 (en) 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
MXPA05007503A (es) * 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US7199149B2 (en) 2003-10-01 2007-04-03 Bristol Myers Squibb Company Monocyclic and bicyclic lactams as factor Xa inhibitors
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007014258A (es) * 2005-05-18 2008-01-22 Wyeth Corp Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos.
CN101213187B (zh) 2005-06-28 2012-06-06 塞诺菲-安万特股份有限公司 作为rho-激酶抑制剂的异喹啉衍生物
WO2007021795A2 (fr) 2005-08-09 2007-02-22 Irm Llc Composes et compositions utiles comme inhibiteurs de proteines kinases
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
CA2651072A1 (fr) 2006-05-01 2007-11-08 Pfizer Products Inc. Composes heterocycliques 2-amino-substitues a cycles fusionnes
US8088793B2 (en) * 2007-08-15 2012-01-03 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8309577B2 (en) * 2008-04-23 2012-11-13 Bristol-Myers Squibb Company Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands
US20100197688A1 (en) 2008-05-29 2010-08-05 Nantermet Philippe G Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
GB0812969D0 (en) * 2008-07-15 2008-08-20 Sentinel Oncology Ltd Pharmaceutical compounds
AU2010208480A1 (en) 2009-02-02 2011-07-28 Msd K.K. Inhibitors of Akt activity
EA026115B1 (ru) * 2010-12-17 2017-03-31 Ф. Хоффманн-Ля Рош Аг Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение

Also Published As

Publication number Publication date
CO6741198A2 (es) 2013-08-30
CN103261167A (zh) 2013-08-21
EP2651899A2 (fr) 2013-10-23
EA201390877A1 (ru) 2013-12-30
AR084280A1 (es) 2013-05-02
CA2817460A1 (fr) 2012-06-21
JP2017031207A (ja) 2017-02-09
MX2013006101A (es) 2013-07-02
TW201307292A (zh) 2013-02-16
US20140088076A1 (en) 2014-03-27
US20160060262A1 (en) 2016-03-03
CN103261167B (zh) 2016-05-04
HK1187606A1 (zh) 2014-04-11
AU2011344270A1 (en) 2013-07-18
US20120322785A1 (en) 2012-12-20
US8623889B2 (en) 2014-01-07
EA026115B1 (ru) 2017-03-31
JP6026427B2 (ja) 2016-11-16
EP2651899B1 (fr) 2017-05-31
JP2014502601A (ja) 2014-02-03
US9206175B2 (en) 2015-12-08
ECSP13012771A (es) 2014-01-31
WO2012080284A2 (fr) 2012-06-21
CR20130338A (es) 2013-08-09
KR20130129244A (ko) 2013-11-27
PH12013501489A1 (en) 2013-08-28
BR112013013790A2 (pt) 2016-09-13
WO2012080284A3 (fr) 2012-09-07

Similar Documents

Publication Publication Date Title
MA34836B1 (fr) Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations
MA32727B1 (fr) Pyrazolylaminopyridines au titre d'inhibiteurs de fak
MA35132B1 (fr) 4-aryl-n-phényl-1,3,5-triazine-2- amines contenant un groupe sulfoximine
MA31763B1 (fr) Inhibiteurs de kinase de type polo
MA33209B1 (fr) Inhibiteurs de la replication du virus de l'hepatite c
MA37942B1 (fr) Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b
MA33240B1 (fr) Inhibiteurs de bêta-sécrétase
MA33360B1 (fr) Composés antiviraux hétérocycliques
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA38175A1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA30057B1 (fr) Nucleosides antiviraux
MA32171B1 (fr) Compose heterocyclique
MA34389B1 (fr) Nouvelles aminopyrazoloquinazolines
EA201101334A1 (ru) Новые соединения бензотиадиазепина, способ их приготовления и фармацевтические композиции, содержащие их
MA38099B1 (fr) Des nouveaux composes triazolopyrazines substitues inhibiteurs des brd4
PE20140189A1 (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MA32941B1 (fr) Composes organiques
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
MA34779B1 (fr) 2-amino-5,5-difluoro-5,6-dihydro-4h-oxazines en tant qu'inhibiteurs de bace 1 et/ou bace2
FR2911339B1 (fr) Derives du furazane, leur preparation et les compositions energetiques les renfermant
MA35104B1 (fr) Inhibiteur du virus de l'hepatite c
MA31834B1 (fr) 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, leur procédé de production et leur utilisation comme anti-inflammatoires
MA30351B1 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation